On September 22, 2026, San Francisco-based Teal Health announced a $22 million Series A led by .406 Ventures, bringing total funding to $45 million and giving the company runway to push its FDA-authorized at-home cervical cancer screening device out of early-adopter territory and into payer, employer and health-system channels. Existing backers Emerson Collective, Forerunner, Labcorp and Serena Ventures all returned; MPower joined as a new investor. Per Tech Funding News, the company previously raised $10 million in 2025, which had put its running total at $23 million.

Why It Matters

At-home HPV self-collection has spent 2026 quietly becoming the most commercially interesting corner of femtech, and this round is the clearest read yet on why. Afterglow has tracked three other entrants this year alone — Color Health adding FDA-cleared Onclarity self-collection to its virtual cancer clinic in June, NHS England mailing kits to four million women in August, and Everlywell partnering with Waters in September to sell into health plans against the NCQA MY2026 care-gap measure. Every one of those moves points at the same structural fact: the bottleneck was never the assay, it was the speculum and the appointment. What separates Teal from the pack is that it is selling a *device* plus a care pathway rather than a lab logistics play, and it is selling into payers ahead of a coverage change rather than after one. That's a bet with a hard date attached. If the 2027 guidance lands as expected, Teal converts a consumer-paid product into a covered benefit overnight and its 59%-underscreened figure becomes a HEDIS closing argument rather than a marketing stat. If the guidance slips, $45 million buys a lot of waiting — but the competitive field will have crowded further by then. For the broader sexual and reproductive health sector, the pattern is worth noting: the femtech companies raising real money right now are not the ones with the best app. They're the ones with an FDA authorization and a reimbursement thesis.

The product is the Teal Wand, an FDA-authorized self-collection device that lets a patient collect her own sample at home for HPV-based cervical cancer screening and mail it to a lab, wrapped in a telehealth visit, secure results delivery and a follow-up-care pathway when something comes back positive. Teal was founded in 2020 by Kara Egan and Dr. Avnesh Thakor, and reached market via an FDA Breakthrough Device Designation and a $1.68 million National Cancer Institute SBIR grant. The company says it has screened thousands of women and recently launched a study with UC Davis evaluating how the device slots into real clinical workflows.

The number Teal is leading with is a targeting number, not a volume number: the company says 59% of women choosing Teal are underscreened — that is, self-collection is reaching the cohort clinic-based screening keeps missing, not just offering a nicer option to women who were going to show up anyway. Roughly one in three American women is not up to date on cervical screening. "Screening is just too difficult today, whether that is finding an appointment, the time in your day to attend, or the physical discomfort," Egan said in the announcement. "Women need an accurate, trusted alternative that makes it easy to screen."

The real thesis is calendar-shaped. Both Femtech Insider and Tech Funding News report Teal expects broader insurance coverage for self-collected cervical screening starting in 2027, following updated federal preventive-services guidance. .406 partner Kathryn Taylor Reddy put it plainly: "With insurance coverage expanding in 2027, Teal Health is positioned to transform how millions of women receive essential preventive healthcare." A $22 million round raised in September 2026 against a reimbursement switch expected to flip in 2027 is, functionally, pre-positioning capital.

Sources

Update — 2026-09-23

Initial entry — story first created.